Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Inhalable insulin Stories

2013-10-15 08:30:25

--Joint Venture Enables Dance Biopharm to Expedite Regulatory and Commercialization Efforts in China-- SAN FRANCISCO, Oct. 15, 2013 /PRNewswire/ -- Dance Biopharm Inc., a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced that it has entered into a joint venture with Harmony Asset for the development of inhaled insulin in China and other Asian countries (excluding Japan). Under the joint venture, Harmony...

2013-10-04 23:00:35

ChinaMarketResearchReports.com adds Latest Report on “China Insulin Industry Report, 2012-2015” to its store. Dallas, TX (PRWEB) October 05, 2013 China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%. Due to high technological content and entry barriers, Chinese insulin market is...

2013-09-24 12:28:48

NEW YORK and Santa Barbara, Calif., Sept. 24, 2013 /PRNewswire-USNewswire/ -- JDRF, Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) are pleased to announce the first successful clinical research trial using the artificial pancreas in conjunction with ultra-rapid-acting inhaled insulin. This represents a groundbreaking potential advancement in the treatment of type 1 diabetes (T1D). It establishes that the disease can...

Inhaled Insulin More Effective Than Injected, Oral Treatments
2013-08-15 05:18:19

redOrbit Staff & Wire Reports - Your Universe Online MannKind Corp. announced on Wednesday its inhaled insulin device was shown to be more effective than injected and oral treatments in two late-stage clinical trials. The product, known as Afrezza, consists of a fast-acting insulin powder delivered via MannKind’s lightweight inhaler. Administered at the start of a meal, Afrezza dissolves immediately upon inhalation and delivers insulin quickly to the blood stream. Peak insulin...

2013-08-13 08:29:03

--Novel Device Shown to be Safe, Reliable and User-Friendly in a Phase 1/2 Clinical Trial SAN FRANCISCO, Aug. 13, 2013 /PRNewswire/ -- Dance Biopharm Inc., a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, recently completed a key clinical study for Adagio, an investigational drug-device combination under development for the treatment of diabetes with the intent to eliminate the need for injections for mealtime insulin....

2013-06-06 08:29:47

NEW YORK, June 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Clovis Oncology Inc. (NASDAQ: CLVS), MannKind Corporation (NASDAQ: MNKD), TESARO Inc. (NASDAQ: TSRO), Peregrine Pharmaceuticals (NASDAQ: PPHM), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports free of charge - including full price targets, industry...

2013-05-10 08:24:40

CUPERTINO, Calif., May 10, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing. Pfizer's disclosure is as follows: "In 2005, King Pharmaceuticals, Inc. (King) entered into an agreement with Pain Therapeutics, Inc. (PT) to develop and commercialize Remoxy. In August 2008, the FDA accepted the NDA for Remoxy that had been submitted by King and PT. In December 2008, the FDA issued a "complete...

2012-09-13 02:26:53

DANBURY, Conn., Sept. 13, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123. "We are pleased to achieve another milestone in the development of BIOD-123. We continue to meet our timelines and project that we will be able to communicate top-line Phase 2 safety and efficacy data in the third calendar quarter of 2013,"...

2012-06-13 06:25:20

SEATTLE, June 13, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO) hosted a community event today to celebrate the official opening of Novo Nordisk's new type 1 Diabetes R&D Center in Seattle, which will explore innovative approaches to treat and prevent type 1 diabetes. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO ) Novo Nordisk, a leader in diabetes care, is the largest global manufacturer of insulin. The new center will combine Novo Nordisk's longstanding...

2012-05-02 02:27:02

DANBURY, Conn., May 2, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering Biodel's ultra-rapid-acting insulin formulations intended for the treatment of patients with diabetes. The allowed claims cover formulations containing insulin or an insulin analog as an active agent, in which hexameric insulin dissociates to monomeric or dimeric forms. The formulations are in different...